Copyright
©The Author(s) 2021.
World J Diabetes. Jan 15, 2021; 12(1): 19-46
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.19
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.19
Figure 8 Silencing of Toll-like receptor-4 expression inhibits miR-155-5p expression.
Rat mesangial cells (RMCs) were transfected with siRNA-TLR4 to silence Toll-like receptor-4 (TLR4) expression and siRNA-NC for 6 h, and the media were then replaced with normal-glucose (NG, 5.5 mmol/L glucose) or high-glucose (HG, 30 mmol/L glucose) medium for 24 h. aP < 0.05 compared with RMCs cultured with normal glucose concentrations; cP < 0.05 compared with RMCs cultured with high glucose concentrations. The expression of miR-155-5p was quantified using real-time polymerase chain reaction. The results were normalized to the expression of the U6 mRNA and are presented as the mean ± SD of six independent experiments. TLR4: Toll-like receptor-4; N: Normal control; NC: Negative control; H: High-glucose.
- Citation: Zhou Y, Ma XY, Han JY, Yang M, Lv C, Shao Y, Wang YL, Kang JY, Wang QY. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop. World J Diabetes 2021; 12(1): 19-46
- URL: https://www.wjgnet.com/1948-9358/full/v12/i1/19.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i1.19